Based on 10+ years’ thorough experience and innovation research, Poietis has developed NGB-R™, a 4th generation multi-modal bioprinter based on unique laser-assisted bioprinting (LAB) technology.
Poietis brings two bioprinters based on Next-Generation Bioprinting platform to the market. NGB-R™ Bioprinter is commercialized for research applications.
NGB-C™ Bioprinter is a clinical-grade, GMP-compliant system dedicated to clinical applications and meet the requirements of translational research and challenges of industrial manufacturing of implantable tissues.
The NGB-R™ Bioprinter represents a revolutionary leap in bioprinting technology, offering unparalleled precision and flexibility for researchers in the fields of tissue engineering and regenerative medicine. Its state-of-the-art capabilities including Multimodality- Bioprinting Technology, patented LAB (Laser Assisted Bioprinting) Technology, In-Line Imaging, Zebr4D AI- assisted software etc., enable the production of complex, three-dimensional tissues to mimic the natural composition and functionality of human organs.
Founded in 2014 as a spin-off from INSERM and the University of Bordeaux, Poietis’ mission is to provide solutions leveraging its proprietary next-generation bioprinting (NGB) platform and bring tissue engineering therapies to patients.